PHARMACEUTICAL NIOSOMES DRUG DELIVERY: A COMPLETE REVIEW OF NEW DELIVERY SYSTEM
Abstract
Over the past ten years, people working in the field of drug delivery systems have become increasingly interested in designing vesicles as a tool to improve drug delivery. A hydrating mixture of cholesterol and nonionic surfactants forms niosomes, which are vesicles. Liposomes, microspheres, engineering science,small emulsions, antibody loaded drug delivery , magnetic microcapsules,implantable pumps, and niosomes are just a few of the unique methods employed to administer these medications. There are two requirements before designing and developing a novel drug delivery system (NDDS). It must first spread the medication at a preset rate and then release an amount of medication at the site of action that is therapeutically efficacious. These requirements cannot be satisfied by conventional dose forms. In essence, niosomes are non-ionic surfactant-based vesicles in which a group of surfactant macromolecules forms a bilayer to form a membrane that entirely seals off an aqueous solution of solute. Targeted medication delivery is made possible by the reasonable circulation persistence of niosomes. An overview of niosome preparation techniques, niosome kinds, characterisation, and applications is also included in this paper.
Due to qualities including improved drug penetration, local depot for continuous drug release, and a rate-limiting membrane for modulating systemic absorption of pharmaceuticals via the skin, niosomes, vesicular nanocarriers, are gaining a lot of attention as prospective transdermal drug delivery systems. There are a number of theories put up to explain why niosomes can improve medication transfer through the skin. This review aims to provide an exhaustive collection of recent studies in this fascinating field, with special emphasis on the methods used to maximise the potential of niosomes. Niosomal carriers are suitable for the transdermal delivery of a variety of pharmacological agents, including antioxidant, anticancer, anti-inflammatory, antimicrobial, and antibacterial molecules.
Downloads
References
Allen TM. Liposomal drug formulations: Rationale for development and what we can expect for the future. Drugs. 1998;56:747–56.
Malhotra M, Jain NK. Niosomes as drug carriers. Indian Drugs. 1994;31:81–6.
Udupa N. Niosomes as drug carriers. In: Jain NK, editor. Controlled and novel drug delivery. 1st edition. New Delhi: CBS Publishers and Distributors; 2002.
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The Preparation and propereties of Niosomes-Non ionic surfactant vesicles. J Pharm Pharmacol. 1985;37:863–8.
Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: An overview. Int J Pharm. 2004;269:1–14.
Hu C, Rhodes DG. Proniosomes: A Novel Drug Carrier Preparation. Int J Pharm. 1999;185:23–35.
Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (noisome) entrapment on the absorption and distribution of methoterxate in mice. J Pharm Pharmacol. 1985;37:237–42.
Szoka F, Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes) Annu Rev Biophys Bioeng. 1980;9:467–508.
Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech. 2009;10:1186–92.
Sheena IP, Singh UV, Kamath R, Uma Devi P, Udupa N. Niosomal withaferin A, with better tumor efficiency. Indian J Pharm Sci. 1998;60:45–8.
Baillie AJ, Coombs GH, Dolan TF, Laurie J. Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol. 1986;38:502–5.
Gregoriadis G. Targeting of drugs: Implications in medicine. Lancet. 1981;2:241–6.
Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (Niosome and Liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol. 1988;40:161–5.
Cummings J, Stuart JF, Calman KC. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. J Chromatogr. 1984;311:125–33.
Suzuki K, Sokan K. The Application of Liposomes to Cosmetics. Cosmetic and Toiletries. 1990;105:65–78.
Alcantar N, Dearborn K, VanAuker M, Toomey R, Hood E. Niosome-hydrogel drug delivery. US 2008/0050445A1. 2008
Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 1992;75:570–5.
Moser P, Marchand-Arvier M, Labrude P, Handjani -Vila RM, Vignerson C. Hemoglobin niosomes. I. Preparation, functional and physico-chemical properties, and stability. Pharma Acta Helv. 1989;64:192–202.
Moser P, Arvier MM, Labrude P, Vignerson C. Niosomes of hemoglobine. II. Vitro interactions with plasma proteins and phagocytes. Pharm Acta Helv. 1990;65:82–92.
Jayaraman SC, Ramachandran C, Weiner N. Topical delivery of erythromycin from various formulations: An in vivo hairless mouse study. J Pharm Sci. 1996;85:1082–4.
Khandare JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. East Pharmacist. 1994;37:61–4.
Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochem Biophys Acta. 1985;816:294–302.
Naresh RA, Chandrashekhar G, Pillai GK, Udupa N. Antiinflammatory activity of Niosome encapsulated diclofenac sodium with Tween-85 in Arthitic rats. Ind J Pharmacol. 1994;26:46–8.
Rogerson A, Cummings J, Willmott N, Florence AT. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol. 1988;40:337–42.
Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm. 2007;328:130–41.
Tavano L, de Cindio B, Picci N, Ioele G, Muzzalupo R. Drug compartmentalization as strategy to improve the physico-chemical properties of diclofenac sodium loaded niosomes for topical applications. Biomed Microdevices. 2014;16:851–858.
Das MK, Palei NN. Sorbitan ester niosomes for topical delivery of rofecoxib. Indian J Exp Biol. 2011;49:438–445.
Rajnish A, Ajay S. Release studies of ketoprofen niosome. J Chem Pharm Res. 2010;1:79–82.
Ammar HO, Ghora M, El-Nahhas SA, Higazy IM. Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int J Pharm. 2011;405:142–152.
Zidan AS, Mokhtar M. Multivariate optimization of formulation variables influencing flurbiprofen proniosomes characteristics. J Pharm Sci. 2011;100:2212–2221.
El-Laithy HM, Shoukry O, Mahran LG. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm. 2011;77:43–55.
Keservani RK, Sharma AK, Ramteke S. Novel vesicular approach for topical delivery of baclofen via niosomes. Lat Am J Pharm. 2010; 29:1364–1370.
Zhang Y, Zhang K, Wu Z, et al. Evaluation of transdermal salidroside delivery using niosomes via in vitro cellular uptake. Int J Pharm. 2015; 478:138–146.
Tavano L, Alfano P, Muzzalupo R, de Cindio B. Niosomes vs microemulsions: new carriers for topical delivery of capsaicin. Colloids Surf B Biointerfaces. 2011;87:333–339.
Tavano L, Muzzalupo R, Picci N, de Cindio B. Co-encapsulation of lipophilic antioxidants into niosomal carriers: Percutaneous permeation studies for cosmeceutical applications. Colloids Surf B Biointerfaces. 2014;114:114–149.
Manosroi A, Chankhampan C, Manosroi W, Manosroi J. Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment. Eur J Pharm Sci. 2013;48:474–483.
Shaker DS, Nasr M, Mostafa M. Bioavailability and hypocholesterolemic effect of proniosomal simvastatin for transdermal delivery. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5:344–351.
Zidan AS, Hosny KM, Ahmed OA, Fahmy UA. Assessment of simvastatin niosomes for pediatric transdermal drug delivery. Drug Deliv. 2014;11:1–14.
El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2015;23:67–74.
Yasam VR, Jakki SL, Natarajan J, et al. Novel vesicular transdermal delivery of nifedipine – preparation, characterization and in vitro/in-vivo evaluation. Drug Deliv. 2014;9:1–12.
Muzzalupo R, Tavano L, Lai F, Picci N. Niosomes containing hydroxyl additives as percutaneous penetration enhancers: effect on the transdermal delivery of sulfadiazine sodium salt. Colloids Surf B Biointerfaces. 2014;123:207–212.
Kong M, Park H, Feng C, Hou L, Cheng X, Chen X. Construction of hyaluronic acid niosome as functional transdermal nanocarrier for tumor therapy. Carbohydr Polym. 2013;94:634–641.
Kassem MA, Esmat S, Bendas ER, El-Komy MH. Efficacy of topical griseofulvin in treatment of tinea corporis. Mycoses. 2006;49:232–235.
Lakshmi PK, Bhaskaran S. Phase II study of topical niosomal urea gel – an adjuvant in the treatment of psoriasis. International Journal of Pharmaceutical Sciences Review and Research. 2011;7:1–7.
Mazda F, Özer AY, Ercan MT. Preparation and characterisation of urea niosomes – in vitro and in vivo studies. STP Pharm Sci. 1997;7:205–214.
Ribeiro de Souza AL, Kiill CP, Kolenyak dos Santos FK, et al. Nanotechnology-based drug delivery systems for dermatomycosis treatment. Curr Nanosci. 2012;8:512–519
Solanki AB, Parikh JR, Parikh RH, Patel MR. Evaluation of different compositions of niosomes to optimize aceclofenac transdermal delivery. Asian Journal of Pharmaceutical Sciences. 2010;5:87–95.
El-Menshawe SF, Hussein AK. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharm Dev Technol. 2013;18:779–786.
El-Badry M, Fetih G, Fathalla D, Shakeel F. Transdermal delivery of meloxicam using niosomal hydrogels: in vitro and pharmacodynamic evaluation. Pharm Dev Technol. 2014;9:1–7.
Manosroi A, Jantrawuta P, Manosroi J. Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm. 2008;360:156–163.
Copyright (c) 2022 IJRDO-Journal of Applied Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
